Jimmy Weterings

Company: Bonito Biosciences

Job title: Vice President & Head of Oligonucleotide Therapeutics

Seminars:

Panel Discussion: The Future of Oligonucleotide Therapeutics: Where Will the Field Be in 5 Years? 4:00 pm

How will advances in conjugation strategies, nanoparticle formulations, and tissue-specific targeting improve oligonucleotide biodistribution and efficacy? Beyond ALS, Huntington’s Disease & Alzheimer’s. What new indications, such as neurogenetic, epilepsies, neurodevelopmental and neuropsychiatric, are emerging for oligonucleotide-based therapies? What hurdles remain in scaling oligonucleotide production, and how will evolving regulatory frameworks shape the clinical and commercial…Read more

day: Day 2